T1	Participants 282 494	patients with epidermal growth factor receptor-expressing, metastatic colorectal carcinoma with disease progression on or following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens
T2	Participants 817 859	patients with metastatic colorectal cancer
